Not checkedNot checked for notices yet.
Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
Diego Bagnasco, Massimiliano Povero, Lorenzo Pradelli and 10 more
World Allergy Organization Journal · 2020
doi:10.1016/j.waojou.2020.100376 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Severe asthma affects about 5-10% of asthmatic patients, representing a serious issue both from both clinical and economic points of view. With this analysis we want to evaluate the clinical and economic impact of mepolizumab, an anti-IL-5 monoclonal antibody recently approved in Italy, for the treatment of the subset of severe asthma patients, refractory to standard treatments and characterized by eosinophilic inflammation.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.